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Hypothesis: In pregnancy, urinary C peptide
creatinine ratio (UCPCR) reflects endogenous insulin
secretion in women with normal glucose tolerance and
type 1 diabetes.
Research design and methods: UCPCR and serum
C peptide were measured in 90 glucose-tolerant women
at 0 and 120 min during a 75 g oral glucose tolerance
test (OGTT) at 28 weeks of gestation. UCPCR was
measured in 2 samples obtained over 10 weeks apart in
7 pregnant women with longstanding type 1 diabetes.
Results: UCPCROGTT and serum C peptideOGTT of
glucose-tolerant women were significantly correlated at 0
and 120 min (rs0.675, 0.541 respectively, p<0.0001). All 7
pregnant women with type 1 diabetes had detectable first
sample UCPCR (median (range) 49 (6–1038) pmol/mmol)
that rose in 6 women by 477 (29–1491) pmol/mmol.
Conclusions: Detectable UCPCR in pregnant women
with normal glucose tolerance and type 1 diabetes is likely
to reflect endogenous insulin secretion and hence β-cell
activity.
INTRODUCTION
Autopsy studies have suggested β-cell prolifer-
ation and neogenesis in human pregnancies,
possibly due to placental factors.1–3 Three
studies involving a total of 55 women with
type 1 diabetes measured serum or plasma C
peptide in pregnancy, showing 49 women to
have detectable C peptide values.4–6 The
ratio of urinary C peptide to the urinary cre-
atinine obtained from a spot urine sample
and expressed as UCPCR is correlated to
serum C peptide outside pregnancy and has
been used to assess residual β-cell function in
women with type 1 diabetes. The current
study investigated the use of UCPCR to assess
β-cell function in pregnant women with
normal glucose tolerance and with type 1
diabetes.
RESEARCH DESIGN AND METHODS
This prospective study carried out at Queen
Charlotte’s Hospital was ethically approved
by the Imperial College Healthcare Tissue
Bank and the Research Ethics Committee
Wales: 12/WA/0196. All women gave
informed written consent.
One hundred women were recruited pro-
spectively to provide an extra blood and urine
sample during a diagnostic 75 g oral glucose
tolerance test (OGTT) at 28 weeks of preg-
nancy for gestational diabetes mellitus (GDM).
All women had one or more risk factors for
GDM according to the National Institute for
Health and Care Excellence (NICE) guide-
lines,7 or were 35 years old or above. All
women were fasted for 8–10 hours and had
passed their ﬁrst void morning urine.
Blood samples were collected at 0 (fasting)
and 120 min (post-75 g OGTT) in 6 mL BD
plastic Vacutainer Plus, silicone coated tubes,
placed on ice prior to separation of serum by
centrifugation. The second void urine
samples at 0 and the 120 min urine sample
were collected in 30 mL polystyrene universal
containers with boric acid preservative.
Serum and urine samples were transferred to
cryotubes and stored at −80°C before analysis.
Seven women with previously diagnosed
type 1 diabetes were recruited to give a non-
Key messages
▸ It has previously been shown in the non preg-
nant state urinary C peptide creatinine ratio
(UCPCR) obtained from a spot urine sample
correlates with serum C peptide concentra-
tion and is a validated method to assess residual
β-cell function.
▸ The current work shows in pregnant glucose
tolerant women at 28 weeks gestation UCPCR
correlates with serum C peptide at 0 and 120
minutes during a 75 g OGTT
▸ UCPCR is detectable in pregnant women with
over 9 years of type 1 diabetes
▸ The UCPCR measurement in pregnancy provides
a practical method for assessing insulin secre-
tion in pregnancy in women with and without
diabetes
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fasting spot urine sample in the antenatal clinic on two
separate occasions. All seven women gave urine samples
that ranged from 10 to 22 weeks apart (ﬁve women
between the ﬁrst and third trimester, one between the
ﬁrst and second and one between the second and third
trimester). Urine samples were handled as described
above.
Urine and serum C peptide was measured by a
two-step chemiluminescent microparticle immunoassay
using an Abbott Diagnostics Architect platform, with a
total coefﬁcient of variation (CV) <10% and a detection
range of 3.33–10 000 pmol/L for undiluted samples.
Initially urinary c peptide measurements, including
those of the seven women with type 1 diabetes, were
analyzed undiluted. Samples exceeding the upper limit
of detection were rerun following an automated 1:10
dilution using the validated Abbott protein containing
diluent. Samples still exceeding the upper limit of detec-
tion were rerun following a manual 1:20 dilution using
the manufactures’ multiassay manual diluent.8
Creatinine was measured using the kinetic alkaline
picrate method with a total CV of ≤6% (Abbott
Architect ci16200 system). The estimated glomerular ﬁl-
tration rate (eGFR) was estimated by the Modiﬁcation of
Diet in Renal Disease (MDRD) formula.
Statistical analysis was performed using SPSS V.22.
Correlations between UCPCROGTT and serum C
peptideOGTT at 0 and 120 min for the glucose-tolerant
women were performed by Spearman’s rank correlation.
RESULTS
Of the 100 women who had an OGTT, 90 were included
for analysis; excluded were 5 women with GDM by NICE
criteria,7 2 with non-singleton pregnancies, 2 with a gesta-
tional age above 31 weeks and 1 with a renal transplant.
The undiluted OGTT urinary samples were above the
upper limit of the C peptide assay detection in 65 of the
fasting and in all 90 of the 120 min samples. Following
an automated 1:10 dilution, 17 of the 120 min samples
remained above the upper range of assay detection.
A 1:20 manual dilution was performed on these 17
samples; however, due to technical difﬁculties during
the subsequent analysis and multiple freeze–thaw cycles,
these samples were discarded.9 Therefore, the analysis of
120 min UCPCR data was performed on the remaining
73 samples.
The 90 glucose-tolerant women had a median age
(range) of 34 (20–49) years, booking body mass index
(BMI) of 23.7 (17.96–39.49) kg/m2 and a gestational
age of 28 (24–29) weeks. The 0 and 120 min serum C
peptideOGTT median (25th–75th range) was 483 (381–
599) and 2254 (1759–2781) pmol/L, respectively. The
UCPCROGTT at 0 and 120 min median (25th–75th
range) were 2796 (1969–3983) and 12 304 (8621–
20 733) pmol/mmol, respectively. The UCPCROGTT and
serum C peptideOGTT were signiﬁcantly correlated at 0
Figure 1 (A) Scatter plot showing the correlation between
fasting second void UCPCR and fasting serum C peptide
during a 75 g OGTT (rs 0.675, p<0.0001). (B) Scatter plot
showing the correlation between 120 min UCPCR and
120 min serum C peptide at 75 g OGTT (rs0.541, p<0.0001).
(C) The changes in UCPCR of seven pregnant women with
type 1 diabetes between two samples taken 10 weeks or
more apart. OGTT, oral glucose tolerance test; UCPCR,
urinary C peptide creatinine ratio.
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and 120 min, rs 0.675, 0.541 (p<0.0001), respectively
(ﬁgure 1A, B).
The seven women had previously been clinically diag-
nosed with type 1 diabetes at a median age of 14.4 (9–
25) years. At booking, they were 35 (29–40) years old,
with 19 (9–31) years duration of diabetes, BMI of 27.4
(20.3–30.1) kg/m2 and glycated hemoglobin of 6.3%
(5.4–9.7%; 47 (36–82) mmol/mol). The eGFR of all
women was >90 mL/min/1.73 m2.
All seven women with type 1 diabetes had detectable
postprandial UCPCR in the ﬁrst and second undiluted
urine samples, median (25th–75th range) 173 (5.4–
1014) and 650 (27.5–2250) pmol/mmol. Six women had
a rise in UCPCR (median rise (25th–75th range) 477
(23–1221) pmol/mmol) whereas one woman had a fall
in UCPCR between the two samples collected at 13 and
31 weeks’ gestation (ﬁgure 1C).
DISCUSSION
Insulin is secreted in equimolar concentrations as C
peptide and UCPCR provides an integrated measure-
ment of insulin secretion over the interval of the urine
collection.10 As an integrated measure it provides a
more informative assessment of insulin secretion over
time than a spot serum C peptide concentration that
has a 20–30 min circulating half-life.11 In addition, the
use of the UCPCR provides a more practical method-
ology due to its ease in collection and processing than
serum C peptide in clinical practice and research.12
The correlation between UCPCROGTT and serum C
peptideOGTT in 90 glucose-tolerant pregnant women
supports the use of the UCPCR to assess insulin secre-
tion during pregnancy. Outside pregnancy, the use of
the UCPCR to assess endogenous insulin secretion is
well established. The published median (25–75th range)
for a mixed meal tolerance test (MMTT) stimulated
UCPCR among 27 glucose-tolerant non-pregnant
women is 4040 (3000–6990) pmol/mmol; however, this
study used a Roche Diagnostic C peptide assay, that
using different assay formats and antibodies.8 13 These
values are approximately a third of the 120 min
UCPCROGTT values of the 73 pregnant glucose-tolerant
women (median and 25–75th range of 12 304 (8621–
20 733) pmol/mmol) in the current study. An increase
in UCPCR and serum C peptide concentration in preg-
nancy is to be expected due to the physiological
decrease in insulin sensitivity that occurs at this time.14
The use of the UCPCR in pregnancy should correct for
the physiological increase in glomerular ﬁltration rate
that occurs throughout pregnancy.15
All seven pregnant women with long-term type 1 dia-
betes had detectable non-fasting UCPCR when ﬁrst mea-
sured, albeit with values approximately a 10th of those
seen in the 90 pregnant women with normal glucose tol-
erance tested at 28 (24–29) weeks’ gestation. The pub-
lished median (25th and 75th range) for a
MMTT-stimulated UCPCR of 58 non-pregnant women
with type 1 diabetes with over 5 years duration is 20
(0–400) pmol/mmol.13 These ranges for UCPCR of
non-pregnant women are approximately a ﬁfth lower
than those seen for the second urine sample among the
seven pregnant women with type 1 diabetes, median
(range) 650 (27.5–2250 pmol/mmol), with three
women having a UCPCR value >1000 pmol/mmol.
However, it has to be recognized that the UCPCR mea-
surements in the current study were performed on
undiluted urine that is standard practice in our labora-
tory for studies in type 1 diabetes. The use of undiluted
24 hours urinary collections has been validated for assay-
ing low C peptide concentrations using the same assay
methodology.8
Three separate studies in pregnant women with type 1
diabetes have examined circulating C peptide, reporting
it either becomes detectable for the ﬁrst time in preg-
nancy or increases during pregnancy in some women.
Our ﬁndings of detectable UCPCR in pregnancy in a
small group of women with longstanding type 1 diabetes
suggests that using UCPCR in pregnancy might be a suit-
able methodology for studying pregnancy-induced β-cell
regeneration or neogenesis in humans.
There are subtle clinical pointers that pregnancy is
related to either β-cell regeneration or neogenesis in
women with type 1 diabetes having increased endogen-
ous bioactive insulin secretion. In early pregnancy, there
is a decrease of exogenous insulin requirement, and
throughout pregnancy a lower than expected incidence
of diabetic ketoacidosis despite a fall in serum bicarbon-
ate levels and accelerated maternal lipolysis and ketosis
in later pregnancy.16
The possibility that residual β-cells in non-pregnant
individuals with type 1 diabetes may emerge from neo-
genesis of pancreatic ductal cells has been suggested.17
Somatolactogenic hormones and hyperglycemia have
been implicated in the enlargement of the pancreatic
islets and β-cell induction and proliferation seen in
rodents.18
The β-cell adaptation due to neogenesis from other
pancreatic cell types, forming new small islets rather
than hyperplasia, has been proposed to occur in
human pregnancy.1 Pregnancy-related factors capable
of neogenesis of the human β-cells could have thera-
peutic implications for the future treatment of type 1
diabetes.
In summary, this study demonstrated that UCPCR pro-
vides a robust and practical means for assessing insulin
secretion during pregnancy, and provides a practical
methodology to assess in future studies the potential for
β-cell adaptation in women with type 1 diabetes.
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